Abliva Investor Relations Material

Abliva AB, engages in the research and development of mitochondrial medicine for the treatment of neurodegenerative diseases in Sweden. The company's lead candidate is NGM282, an engineered hormone that drives expression of the human glucokinase gene, which is in Phase 2b/3a clinical study as a once-weekly treatment for type 2 diabetes and has completed Phase 1b/2a clinical study to treat non-alcoholic steatohepatitis; and completed a Phase 2 clinical study in patients with primary biliary cholangitis disease.